Filing Details
- Accession Number:
- 0001140361-17-035549
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-14 17:09:15
- Reporting Period:
- 2017-09-13
- Accepted Time:
- 2017-09-14 17:09:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012477 | Avadel Pharmaceuticals Plc | AVDL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1661781 | T. Phillandas Thompson | Block 10-1, Blanchardstown Corporate Park, Ballycoolin Dublin L2 15 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Adss | Acquisiton | 2017-09-13 | 5,000 | $9.36 | 63,000 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Adss | Stock Option (right to buy) | $7.36 | 2023-12-12 | 100,000 | 100,000 | Direct | |
| Adss | Stock Option (right to buy) | $16.30 | 2024-12-11 | 95,000 | 95,000 | Direct | |
| Adss | Stock Option (right to buy) | $14.35 | 2025-12-10 | 100,000 | 100,000 | Direct | |
| Adss | Stock Option (right to buy) | $10.40 | 2026-12-14 | 100,000 | 100,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2023-12-12 | 100,000 | 100,000 | Direct |
| 2024-12-11 | 95,000 | 95,000 | Direct |
| 2025-12-10 | 100,000 | 100,000 | Direct |
| 2026-12-14 | 100,000 | 100,000 | Direct |
Footnotes
- The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts..
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.34 to $9.38, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
- Includes (a) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 20,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (c) 18,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date.
- Options become exercisable as to 23,750 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Billionaire Hedge Funds
